As the above results indicate, ATL-I can inhibit ccRCC proliferation, invasion, and migration and exhibits robust antiangiogenic capacity by inhibiting the EPAS1-VEGFA signaling pathway. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.